Vivimed Labs, a niche specialty chemicals and pharmaceuticals company, has received a favourable outcome for its API manufacturing facility located in Lliga de Vail, Spain post its US Food and Drug Administration (USFDA) inspection. The audit was conducted during the second week of September and concluded on September 18, 2015.
On completion of the inspection the USFDA inspectors concluded that the facility, its systems and practices comply with USFDA requirements with no observations reported on the form 483.
The company during the last one year has had a satisfactory outcome on the regulatory compliance front with all four of its USFDA approved manufacturing plants including Sant Celoni, Spain (May 2015), Alathur, India (February 2015), Cuernavaca, Mexico (September 2014) and now Lliga de Vail, Spain.
Vivimed Labs is a listed company engaged in the business of manufacturing products (active ingredients, formulations, etc) for pharmaceutical, personal care and colour chemistry industry. VLL (Consolidated) has manufacturing facilities in India and Overseas.
